A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Feb 2018 Study protocol amended with addition of third treatment arm which includes apatinib dose as 375mg/d (SHR-1210 200mg,q2w plus apatinib 375mg/d).
- 06 Feb 2018 Planned end date changed from 31 Aug 2018 to 30 Jun 2019.
- 06 Feb 2018 Planned primary completion date changed from 27 Feb 2018 to 27 Dec 2018.